Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Responses to second-line treatments appear to vary according to patient characteristics, for example, BCR-ABL mutation type. Although targeted agents are effective for CML, they do not represent a ...

Researchers reported that while the third-generation BCR-ABL1 TKIs had previously been shown to be safe and effective among patients with CML who were either resistant or intolerant to two prior TKIs ...

The immediate pressing clinical issues in the CP-CML setting include patients with T315I mutations, which account for 15% of imatinib resistance mutations. At present, the therapeutic options for ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Here’s what the data revealed. The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at ...

In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation. Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a ...

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. A model ...

¥ÿÿW1Ž­ Õ^ ‘¦õf>œOáí ÀŒ$Bõ îï! ªUBÜ öªøõÇ_ÿü÷ç ®ÿÿÿ `hdlbjfnaiemckgïàèäìâêæîáéåíãëçï?Ó¬úû\N/R«(± @Àƒ¡ÛR´T ...